[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100408562":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":38,"locations":44,"responsibleParty":62,"collaborators":26,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":26,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"University of Kentucky","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard of Care","PLACEBO_COMPARATOR","Participants in this group will receive standard of care as well as a saline infusion during the study period.",[13],"Drug: Saline",{"label":15,"type":16,"description":17,"interventionNames":18},"Sub-Dissociative Ketamine","EXPERIMENTAL","Participants in this group will receive standard of care as well as a continuous ketamine infusion at the induction of anesthesia and for 48 hours postoperatively.",[19],"Drug: Ketamine",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Saline","Saline infusion",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Ketamine","Continuous ketamine infusion at a dose of 0.2 mg\u002Fkg\u002Fhr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.",[15],[32,35],{"name":33,"affiliation":5,"role":34},"Anna Rockich, Pharm D","STUDY_DIRECTOR",{"name":36,"affiliation":5,"role":37},"Samuel Tyagi, MD","PRINCIPAL_INVESTIGATOR",[39],{"name":40,"role":41,"phone":42,"phoneExt":26,"email":43},"Eric Johnson, PharmD","CONTACT","8593235722","eric.johnson@uky.edu",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"University of Kentucky Medical Center","RECRUITING","Lexington","Kentucky","40536","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-84.47772,37.98869,{"lat":57,"lon":56},[60],{"name":40,"role":41,"phone":61,"phoneExt":26,"email":43},"859-323-5722",{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Sam Tyagi","Assistant Professor","100408562","phase-2-ketamine-in-patients-undergoing-tevar-procedures-receiving-nci-100408562",false,"NCT04600089","Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI","A Randomized, Double-blind, Placebo-controlled, Study to Identify the Opioid-sparing Effects, and Pain-reduction Potential of Low Dose Ketamine on Patients Undergoing TEVAR Procedures Receiving NCI","2020Ketamine","Inclusion Criteria:\n\n* willing to give informed consent\n* scheduled for elective thoracic aorta repair or thoracoabdominal aortic repair\n* requires naloxone continuous infusion for spinal prophylaxis\n\nExclusion Criteria:\n\n* allergy to ketamine, acetaminophen, or fentanyl\n* diagnosis of schizophrenia\n* history of hydrocephalus or central nervous system mass\n* incarcerated individuals\n* pregnant or lactating individuals","ALL","18 Years","90 Years",{"count":78,"type":79},30,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI).",[85,86,87],"Descending Aortic Dissection","Postoperative Pain","Thoracoabdominal Aortic Aneurysm",[89,90,91,92],"naloxone","ketamine","aortic repair","spinal cord ischemia","2025-10-15",{"date":95,"type":96},"2025-10-20","ACTUAL",{"date":98,"type":96},"2020-12-08",{"date":100,"type":79},"2027-08",{"name":64,"class":6},1]